Drug Profile


Alternative Names: CDP-4940; UCB-4940

Latest Information Update: 25 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator UCB
  • Class Antipsoriatics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action IL17A protein inhibitors; IL17F protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ankylosing spondylitis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • No development reported Psoriasis

Most Recent Events

  • 21 Jul 2017 Adverse event and efficacy data released by UCB from the phase IIb BE ABLE trial in Plaque psoriasis, which met the primary endpoint
  • 05 Jul 2017 UCB Biopharma plans a phase II trial for Ankylosing spondylitis (Treatment-experienced) on 27 July, 2017 (NCT03215277)
  • 01 Apr 2017 UCB completes a phase II trial in Rheumatoid arthritis (Adjunctive treatment) in United Kingdom, Czech Republic, Hungary, Moldova, Poland, Russia, Slovakia (NCT02430909)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top